Juvenile laryngeal papillomatosis - Immunisation with the polyvalent vaccine Gardasil®;Juvenile larynxpapillomatose - Impfung mit dem polyvalenten spaltimpfstoff Gardasil®

Laryngo- Rhino- Otologie

Volumn 87, Issue 11, 2008, Pages 796-798

  Förster, Gerhard ^a,e   Boltze, C ^b   Seidel, J ^c   Pawlita, M ^d   Muller A ^a  

^a Klinik für HNO Heilkunde Plastische Operationen

^b UNIVERSITY OF ROSTOCK   (Germany)

^c Klinik für Kinder und Jugendmedizin

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e SRH Wald Klinikum Gera   (Germany)

Author keywords

Case report; Gardasil; HPV; Laryngeal papillomatosis; Larynx; Papillomavirus

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CASE REPORT; DISEASE COURSE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN TISSUE; IMMUNIZATION; IN SITU HYBRIDIZATION; LARYNX PAPILLOMATOSIS; MALE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL;

ALPHAPAPILLOMAVIRUS; ANTIBODIES, VIRAL; FLUORESCENCE; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 6; HUMANS; IMMUNIZATION; IN SITU HYBRIDIZATION; INFANT; LARYNGEAL NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; PAPILLOMA; PAPILLOMAVIRUS VACCINES; POLYMERASE CHAIN REACTION; TIME FACTORS;

EID: 57049116514     PISSN: 09358943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1077527     Document Type: Article

References (23)

1. Derkay CS. Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg 1995; 121: 1386-1391
2. Alberico S, Pinzano R, Comar M et al. Maternal-fetal transmission of human papillomavirus. Minerva Ginecol 1996; 48: 199-204
3. Terry RM, Lewis FA, Griffiths S, Wells M, Bird CC. Demonstration of human papillomavirus types 6 and 11 in juvenile laryngeal papillomatosis by in-situ DNA hybridization. J Pathol 1987; 153: 245-248
4. Mounts P, Shah KV, Kashima H. Viral etiology of juvenile- and adult-onset squamous papilloma of the larynx. Proc Natl Acad Sci USA 1982; 79: 5425-5429
5. Reeves WC, Ruparelia SS, Swanson KI et al. National registry for juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2003; 129: 976-982
6. Ruparelia S, Unger ER, Nisenbaum R, Derkay CS, Reeves WC. Predictors of remission in juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2003; 129: 1275-1278
7. Kimberlin DW. Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomatosis. Antiviral Res 2004; 63: 141-151
8. Gerein V, Rastorguev E, Gerein J, Draf W, Schirren J. Incidence, age at onset, and potential reasons of malignant transformation in recurrent respiratory papillomatosis patients: 20 years experience. Otolaryngol Head Neck Surg 2005; 132: 392-394
9. Aaltonen LM, Rihkanen H, Vaheri A. Human papillomavirus in larynx. Laryngoscope 2002; 112: 700-707
10. Stamataki S, Nikolopoulos TP, Korres S et al. Juvenile recurrent respiratory papillomatosis: still a mystery disease with difficult management. Head Neck 2007; 29: 155-162
11. Gerein V, Rastorguev E, Gerein J, Jecker P, Pfister H. Use of interferon-alpha in recurrent respiratory papillomatosis: 20-year follow-up. Ann Otol Rhinol Laryngol 2005; 114: 463-471
12. Pudszuhn A, Welzel C, Bloching M, Neumann K. Intralesional Cidofovir application in recurrent laryngeal papillomatosis. Eur Arch Otorhinolaryngol 2007; 264: 63-70
13. Neumann K, Pudszuhn A, Welzel C, Bartel-Friedrich S, Passmann M. Intralesional cidofovir injections for recurrent laryngeal papillomatosis: first results. Laryngo-Rhino-Otol 2003; 82: 700-706
14. Shikowitz MJ, Abramson AL, Steinberg BM et al. Clinical trial of photodynamic therapy with meso-tetra (hydroxyphenyl) chlorin for respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2005; 131: 99-105
15. Pashley NR. Can mumps vaccine induce remission in recurrent respiratory papilloma? Arch Otolaryngol Head Neck Surg 2002; 128: 783-786
16. Villa LL, Costa RL, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95: 1459-1466
17. Glastetter E, Kaufmann AM. Humoral and cellular immune response in HPV vaccination. Hautarzt 2007; 58: 493-500
18. Garland SM, Hernandez-Avila M, Wheeler CM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-1943
19. Maloney EM, Unger ER, Tucker RA et al. Longitudinal measures of human papillomavirus 6 and 11 viral loads and antibody response in children with recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2006; 132: 711-715
20. Chen BB, Zhao KN, Liu XS et al. The detection and significance of human papilloma virus 11b virus like particles and its serum antibody in juvenile larynx papilloma. Zhonghua Er Bi Yan Hou Ke Za Zhi 2003; 38: 417-420
21. Roda Husman A-M, Walboomers JMM, Brule AJC, Meijer CJLM, Snijders PJF. The use of geneal primers PG5 and PG6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995; 76: 1057-1062
22. Hallez S, Simon P, Maudoux F et al. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother 2004; 53: 642-650
23. Waterboer T, Sehr P, Michael KM et al. Multiplex Human Papillomavirus Serology Based on in Situ-Purified Glutathione S-Transferase Fusion Proteins. Clin Chem 2005; 51: 1845-1853